Cannabinoid (PRECIPITANT) Medication Affecting the Metabolism of Another (OBJECT) Medication

Pennsylvania State University, College of Medicine, Dept of Pharmacology (Hershey, PA)

https://sites.psu.edu/cannabinoid
Cannabinoid
Generic Name Medication Drug Effect Cannabinoid as the Enzyme Enzyme Source
Class Enzyme/Metabolism CYP1A2 CYP2B6 CYP2C8 CYP2C9 CYP2C19 CYP2E1 CYP3A4 UGT1A9 UGT2B7 Source
(OBJECT) (OBJECT) (PRECIPITANT) Inhibitor Inducer Date
(PRECIPITANT)
acenocoumarol (VKA) ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
acenocoumarol (VKA) ↑ CBD Cannabidiolol √ CYP2C19 Substrate w/NTI √ DrugBank.ca 12/4/2019
acenocoumarol (VKA) ↑ CBD Cannabidiolol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
acenocoumarol (VKA) ↑ THC Dronabinol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
acenocoumarol (VKA) ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
acenocoumarol (VKA) ↑ THC Nabilone √ (Mod) CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
acenocoumarol (VKA) ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
acenocoumarol (VKA) ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
alfentanil ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
alfentanil ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
alfentanil ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
alfentanil ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
alosetron ↑↓ CBD Cannabidiolol √ √ CYP1A2 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
alosetron ↓ THC/CBD Nabiximols √ CYP1A2 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
alprazolam ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
alprazolam ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
alprazolam ↑↓ THC/CBD Nabiximols √ √ CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
alprazolam ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
aminophylline ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
aminophylline ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
aminophylline ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
aminophylline ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
amiodarone ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
amiodarone ↑ CBD Cannabidiolol √ CYP2C19 Substrate w/NTI √ DrugBank.ca 12/4/2019
amiodarone ↑ CBD Cannabidiolol √ CYP2C8 Substrate w/NTI √ DrugBank.ca 1/2/2020
amiodarone ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
amiodarone ↑ THC Nabilone √ (Mod) CYP2C8 Substrate w/NTI √ DrugBank.ca 1/2/2020
amiodarone ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
amiodarone ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
amitriptyline ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
amitriptyline ↑↓ CBD Cannabidiolol √ √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
amitriptyline ↑ CBD Cannabidiolol √ CYP2C19 Substrate w/NTI √ DrugBank.ca 12/4/2019
amitriptyline ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
amitriptyline ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
amitriptyline ↓ THC/CBD Nabiximols √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
amitriptyline ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
amphotericin B ↑ THC Dronabinol Protein Binding (LexiComp® Clinical Drug Info) online.lexi.com 2/10/2020
aprepitant ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
aprepitant ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
aprepitant ↑↓ THC/CBD Nabiximols √ √ CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
aprepitant ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
argatroban ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
argatroban ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
astemizole ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
astemizole ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
atorvastatin ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
atorvastatin ↑↓ THC/CBD Nabiximols √ √ CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
avanafil ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
avanafil ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
avanafil ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
avanafil ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
bromocriptine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
bromocriptine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
budesonide ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
budesonide ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
budesonide ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
budesonide ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
bupropion ↑↓ CBD Cannabidiolol √ √ CYP2B6 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
buspirone ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
buspirone ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
buspirone ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
buspirone ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
busulfan ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
busulfan ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
caffeine ↑↓ CBD Cannabidiolol √ √ CYP1A2 Sensitive Index Substrate (Table 2-1) √ FDA.gov 9/26/2016
caffeine ↑↓ CBD Cannabidiolol √ √ CYP1A2 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
caffeine ↓ THC/CBD Nabiximols √ CYP1A2 Sensitive Index Substrate (Table 2-1) √ FDA.gov 9/26/2016
caffeine ↓ THC/CBD Nabiximols √ CYP1A2 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
carbamazepine ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
carbamazepine ↑ CBD Cannabidiolol √ UGT2B7 Substrate w/NTI √ DrugBank.ca 1/2/2020
carbamazepine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019

List Updated April 13, 2020

While every attempt has been made to provide the most comprehensive list of potential drug-drug interactions,
there may be OTC, herbal, and prescription medications not included within this list. Page 1 of 7
 Cannabinoid (PRECIPITANT) Medication Affecting the Metabolism of Another (OBJECT) Medication
Pennsylvania State University, College of Medicine, Dept of Pharmacology (Hershey, PA)
https://sites.psu.edu/cannabinoid
Cannabinoid
Generic Name Medication Drug Effect Cannabinoid as the Enzyme Enzyme Source
Class Enzyme/Metabolism CYP1A2 CYP2B6 CYP2C8 CYP2C9 CYP2C19 CYP2E1 CYP3A4 UGT1A9 UGT2B7 Source
(OBJECT) (OBJECT) (PRECIPITANT) Inhibitor Inducer Date
(PRECIPITANT)
carbamazepine ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
carbamazepine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
carbamazepine ↑ THC/CBD Nabiximols √ UGT2B7 Substrate w/NTI √ DrugBank.ca 1/2/2020
celecoxib ↑ CBD Cannabidiolol √ CYP2C9 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
celecoxib ↑ THC Dronabinol √ CYP2C9 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
celecoxib ↑ THC Nabilone √ (Mod) CYP2C9 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
cisapride ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
cisapride ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
clindamycin ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
clindamycin ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
clobazam (N-desmethylclobazam) ↑ CBD Cannabidiolol √ CYP2C19 Substrate (Epidiolex®) Prescribing Information, 7.2 √ Prescribing Info 6/2018
clomipramine ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
clomipramine ↑↓ CBD Cannabidiolol √ √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
clomipramine ↑ CBD Cannabidiolol √ CYP2C19 Substrate w/NTI √ DrugBank.ca 12/4/2019
clomipramine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
clomipramine ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
clomipramine ↓ THC/CBD Nabiximols √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
clomipramine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
clonidine ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
clonidine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
clonidine ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
clonidine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
clorindione (VKA) ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
clorindione (VKA) ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
clozapine ↑↓ CBD Cannabidiolol √ √ CYP1A2 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
clozapine ↓ THC/CBD Nabiximols √ CYP1A2 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
colchicine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
colchicine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
colchicine ↑↓ THC/CBD Nabiximols √ √ CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
colchicine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
conivaptan ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
conivaptan ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
conivaptan ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
conivaptan ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
cyclobenzaprine ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
cyclobenzaprine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
cyclobenzaprine ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
cyclobenzaprine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
cylcosporine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
cylcosporine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
dabigatran etexilate ↑ CBD Cannabidiolol √ UGT1A9 Substrate w/NTI √ DrugBank.ca 1/2/2020
dabigatran etexilate ↑ CBD Cannabidiolol √ UGT2B7 Substrate w/NTI √ DrugBank.ca 1/2/2020
dabigatran etexilate ↑ THC/CBD Nabiximols √ UGT1A9 Substrate w/NTI √ DrugBank.ca 1/2/2020
dabigatran etexilate ↑ THC/CBD Nabiximols √ UGT2B7 Substrate w/NTI √ DrugBank.ca 1/2/2020
darifenacin ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
darifenacin ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
darifenacin ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
darifenacin ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
darunavir ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
darunavir ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
darunavir ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
darunavir ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
dasatinib ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
dasatinib ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
dasatinib ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
dasatinib ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
desipramine ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
desipramine ↑↓ CBD Cannabidiolol √ √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
desipramine ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
desipramine ↓ THC/CBD Nabiximols √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
diazepam ↑ CBD Cannabidiolol √ CYP2C19 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
dicoumarol (VKA) ↑ CBD Cannabidiolol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
dicoumarol (VKA) ↑ THC Dronabinol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
dicoumarol (VKA) ↑ THC Nabilone √ (Mod) CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
diflunisal ↑ CBD Cannabidiolol √ UGT1A9 Substrate (Epidiolex®) Prescribing Information, 7.2 √ Prescribing Info 6/2018
digitoxin ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
digitoxin ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
dihydroergotamine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
dihydroergotamine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
diphenadione (VKA) ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
diphenadione (VKA) ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019

List Updated April 13, 2020

While every attempt has been made to provide the most comprehensive list of potential drug-drug interactions,
there may be OTC, herbal, and prescription medications not included within this list. Page 2 of 7
 Cannabinoid (PRECIPITANT) Medication Affecting the Metabolism of Another (OBJECT) Medication
Pennsylvania State University, College of Medicine, Dept of Pharmacology (Hershey, PA)
https://sites.psu.edu/cannabinoid
Cannabinoid
Generic Name Medication Drug Effect Cannabinoid as the Enzyme Enzyme Source
Class Enzyme/Metabolism CYP1A2 CYP2B6 CYP2C8 CYP2C9 CYP2C19 CYP2E1 CYP3A4 UGT1A9 UGT2B7 Source
(OBJECT) (OBJECT) (PRECIPITANT) Inhibitor Inducer Date
(PRECIPITANT)
dofetilide ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
dofetilide ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
dosulepin ↑↓ CBD Cannabidiolol √ √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
dosulepin ↓ THC/CBD Nabiximols √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
doxepin ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
doxepin ↑ CBD Cannabidiolol √ CYP2C19 Substrate w/NTI √ DrugBank.ca 12/4/2019
doxepin ↑ CBD Cannabidiolol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
doxepin ↑ THC Dronabinol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
doxepin ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
doxepin ↑ THC Nabilone √ (Mod) CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
doxepin ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
doxepin ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
dronedarone ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
dronedarone ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
dronedarone ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
dronedarone ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
duloxetine ↑↓ CBD Cannabidiolol √ √ CYP1A2 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
duloxetine ↓ THC/CBD Nabiximols √ CYP1A2 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
ebastine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
ebastine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
ebastine ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
ebastine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
efavirenz ↑↓ CBD Cannabidiolol √ √ CYP2B6 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
eletriptan ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
eletriptan ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
eletriptan ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
eletriptan ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
eliglustat ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
eliglustat ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
eliglustat ↑↓ THC/CBD Nabiximols √ √ CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
eliglustat ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
eplerenone ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
eplerenone ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
eplerenone ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
eplerenone ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
ergotamine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
ergotamine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
esketamine ↑↓ CBD Cannabidiolol √ √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
esketamine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
esketamine ↓ THC/CBD Nabiximols √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
esketamine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
ethiny estradiol (Oral Contraceptives) ↓ THC/CBD Nabiximols √ UGT1A9 Substrate √ DrugBank.ca 1/2/2020
ethiny estradiol (Oral Contraceptives) ↓ THC/CBD Nabiximols √ UGT2B7 Substrate √ DrugBank.ca 1/2/2020
ethosuximide ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
ethosuximide ↑ THC Nabilone √ (Weak) CYP2E1 Substrate w/NTI √ DrugBank.ca 1/2/2020
ethosuximide ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
ethyl biscoumacetate (VKA) ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
ethyl biscoumacetate (VKA) ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
everolimus ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
everolimus ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
everolimus ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
everolimus ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
felodipine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
felodipine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
felodipine ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
felodipine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
fenofibrate ↑ CBD Cannabidiolol √ UGT1A9 Substrate (Epidiolex®) Prescribing Information, 7.2 √ Prescribing Info 6/2018
fentanyl ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
fentanyl ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
fluindione (VKA) ↑ CBD Cannabidiolol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
fluindione (VKA) ↑ THC Dronabinol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
fluindione (VKA) ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
fluindione (VKA) ↑ THC Nabilone √ (Mod) CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
fluindione (VKA) ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
fosaprepitant ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
fosaprepitant ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
fosphenytoin ↑ CBD Cannabidiolol √ CYP2C19 Substrate w/NTI √ DrugBank.ca 12/4/2019
fosphenytoin ↑ CBD Cannabidiolol √ CYP2C8 Substrate w/NTI √ DrugBank.ca 1/2/2020
fosphenytoin ↑ CBD Cannabidiolol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
fosphenytoin ↑ THC Dronabinol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
fosphenytoin ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019

List Updated April 13, 2020

While every attempt has been made to provide the most comprehensive list of potential drug-drug interactions,
there may be OTC, herbal, and prescription medications not included within this list. Page 3 of 7
 Cannabinoid (PRECIPITANT) Medication Affecting the Metabolism of Another (OBJECT) Medication
Pennsylvania State University, College of Medicine, Dept of Pharmacology (Hershey, PA)
https://sites.psu.edu/cannabinoid
Cannabinoid
Generic Name Medication Drug Effect Cannabinoid as the Enzyme Enzyme Source
Class Enzyme/Metabolism CYP1A2 CYP2B6 CYP2C8 CYP2C9 CYP2C19 CYP2E1 CYP3A4 UGT1A9 UGT2B7 Source
(OBJECT) (OBJECT) (PRECIPITANT) Inhibitor Inducer Date
(PRECIPITANT)
fosphenytoin ↑ THC Nabilone √ (Mod) CYP2C8 Substrate w/NTI √ DrugBank.ca 1/2/2020
fosphenytoin ↑ THC Nabilone √ (Mod) CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
fosphenytoin ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
gemfibrozil ↑ CBD Cannabidiolol √ UGT2B7 Substrate (Epidiolex®) Prescribing Information, 7.2 √ Prescribing Info 6/2018
glimepiride ↑ CBD Cannabidiolol √ CYP2C9 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
glimepiride ↑ THC Dronabinol √ CYP2C9 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
glimepiride ↑ THC Nabilone √ (Mod) CYP2C9 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
ibrutinib ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
ibrutinib ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
ibrutinib ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
ibrutinib ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
imipramine ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
imipramine ↑↓ CBD Cannabidiolol √ √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
imipramine ↑ CBD Cannabidiolol √ CYP2C19 Substrate w/NTI √ DrugBank.ca 12/4/2019
imipramine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
imipramine ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
imipramine ↓ THC/CBD Nabiximols √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
imipramine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
indinavir ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
indinavir ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
indinavir ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
indinavir ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
isavuconazole ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
isavuconazole ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
lamotrigine ↑ CBD Cannabidiolol √ UGT2B7 Substrate (Epidiolex®) Prescribing Information, 7.2 √ Prescribing Info 6/2018
lansoprazole ↑ CBD Cannabidiolol √ CYP2C19 Sensitive Index Substrate (Table 2-1) √ FDA.gov 9/26/2016
lansoprazole ↑ CBD Cannabidiolol √ CYP2C19 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
levacetylmethadol ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
levacetylmethadol ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
levothyroxine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
levothyroxine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
lofepramine ↑↓ CBD Cannabidiolol √ √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
lofepramine ↓ THC/CBD Nabiximols √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
lomitapide ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
lomitapide ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
lomitapide ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
lomitapide ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
lopinavir ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
lopinavir ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
lorazepam ↑ CBD Cannabidiolol √ UGT2B7 Substrate (Epidiolex®) Prescribing Information, 7.2 √ Prescribing Info 6/2018
lovastatin ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
lovastatin ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
lovastatin ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
lovastatin ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
lurasidone ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
lurasidone ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
lurasidone ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
lurasidone ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
maraviroc ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
maraviroc ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
maraviroc ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
maraviroc ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
melatonin ↑↓ CBD Cannabidiolol √ √ CYP1A2 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
melatonin ↓ THC/CBD Nabiximols √ CYP1A2 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
melitracen ↑↓ CBD Cannabidiolol √ √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
melitracen ↓ THC/CBD Nabiximols √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
meperidine ↑↓ CBD Cannabidiolol √ √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
meperidine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
meperidine ↓ THC/CBD Nabiximols √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
meperidine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
mephenytoin ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
mephenytoin ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
mephenytoin (S-Enantiomer) ↑ CBD Cannabidiolol √ CYP2C19 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
methysergide ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
methysergide ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
midazolam ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Index Substrate (Table 2-1) √ FDA.gov 9/26/2016
midazolam ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
midazolam ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
midazolam ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Index Substrate (Table 2-1) √ FDA.gov 9/26/2016
midazolam ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
midazolam ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019

List Updated April 13, 2020

While every attempt has been made to provide the most comprehensive list of potential drug-drug interactions,
there may be OTC, herbal, and prescription medications not included within this list. Page 4 of 7
 Cannabinoid (PRECIPITANT) Medication Affecting the Metabolism of Another (OBJECT) Medication
Pennsylvania State University, College of Medicine, Dept of Pharmacology (Hershey, PA)
https://sites.psu.edu/cannabinoid
Cannabinoid
Generic Name Medication Drug Effect Cannabinoid as the Enzyme Enzyme Source
Class Enzyme/Metabolism CYP1A2 CYP2B6 CYP2C8 CYP2C9 CYP2C19 CYP2E1 CYP3A4 UGT1A9 UGT2B7 Source
(OBJECT) (OBJECT) (PRECIPITANT) Inhibitor Inducer Date
(PRECIPITANT)
montelukast ↑ CBD Cannabidiolol √ CYP2C8 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
montelukast ↑ THC Nabilone √ (Mod) CYP2C8 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
morphine ↑ CBD Cannabidiolol √ UGT2B7 Substrate (Epidiolex®) Prescribing Information, 7.2 √ Prescribing Info 6/2018
mycophenolic acid ↑ CBD Cannabidiolol √ UGT1A9 Substrate w/NTI √ DrugBank.ca 1/2/2020
mycophenolic acid ↑ CBD Cannabidiolol √ UGT2B7 Substrate w/NTI √ DrugBank.ca 1/2/2020
mycophenolic acid ↑ THC/CBD Nabiximols √ UGT1A9 Substrate w/NTI √ DrugBank.ca 1/2/2020
mycophenolic acid ↑ THC/CBD Nabiximols √ UGT2B7 Substrate w/NTI √ DrugBank.ca 1/2/2020
naloxegol ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
naloxegol ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
naloxegol ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
naloxegol ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
nisoldipine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
nisoldipine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
nisoldipine ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
nisoldipine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
nortriptyline ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
nortriptyline ↑↓ CBD Cannabidiolol √ √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
nortriptyline ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
nortriptyline ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
nortriptyline ↓ THC/CBD Nabiximols √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
nortriptyline ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
omeprazole ↑ CBD Cannabidiolol √ CYP2C19 Sensitive Index Substrate (Table 2-1) √ FDA.gov 9/26/2016
omeprazole ↑ CBD Cannabidiolol √ CYP2C19 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
paclitaxel ↑ CBD Cannabidiolol √ CYP2C8 Substrate w/NTI √ DrugBank.ca 1/2/2020
paclitaxel ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
paclitaxel ↑ THC Nabilone √ (Mod) CYP2C8 Substrate w/NTI √ DrugBank.ca 1/2/2020
paclitaxel ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
pentobarbital ( ↑ elim t½ by 4 hours) ↑ THC Dronabinol √ Dronabinol (Syndros®) Prescribing Information, 12.3 Prescribing Info 9/2018
phenobarbital ↑ CBD Cannabidiolol √ CYP2C19 Substrate w/NTI √ DrugBank.ca 12/4/2019
phenprocoumon (VKA) ↑ CBD Cannabidiolol √ CYP2C8 Substrate w/NTI √ DrugBank.ca 1/2/2020
phenprocoumon (VKA) ↑ CBD Cannabidiolol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
phenprocoumon (VKA) ↑ THC Dronabinol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
phenprocoumon (VKA) ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
phenprocoumon (VKA) ↑ THC Nabilone √ (Mod) CYP2C8 Substrate w/NTI √ DrugBank.ca 1/2/2020
phenprocoumon (VKA) ↑ THC Nabilone √ (Mod) CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
phenprocoumon (VKA) ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
phenytoin ↑ CBD Cannabidiolol √ CYP2C19 Substrate w/NTI √ DrugBank.ca 12/4/2019
phenytoin ↑ CBD Cannabidiolol √ CYP2C8 Substrate w/NTI √ DrugBank.ca 1/2/2020
phenytoin ↑ CBD Cannabidiolol √ CYP2C9 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
phenytoin ↑ THC Dronabinol √ CYP2C9 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
phenytoin ↑ THC Dronabinol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
phenytoin ↑ THC Nabilone √ (Mod) CYP2C8 Substrate w/NTI √ DrugBank.ca 1/2/2020
phenytoin ↑ THC Nabilone √ (Mod) CYP2C9 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
phenytoin ↑ THC Nabilone √ (Mod) CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
pimozide ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
pimozide ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
pimozide ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
pimozide ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
pimozide ↑↓ THC/CBD Nabiximols √ √ CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
pimozide ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
pioglitazone ↑ CBD Cannabidiolol √ CYP2C8 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
pioglitazone ↑ THC Nabilone √ (Mod) CYP2C8 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
pirfenidone ↑↓ CBD Cannabidiolol √ √ CYP1A2 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
pirfenidone ↓ THC/CBD Nabiximols √ CYP1A2 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
propofol ↑ CBD Cannabidiolol √ UGT1A9 Substrate (Epidiolex®) Prescribing Information, 7.2 √ Prescribing Info 6/2018
quetiapine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
quetiapine ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
quinidine ↑ CBD Cannabidiolol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
quinidine ↑ THC Dronabinol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
quinidine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
quinidine ↑ THC Nabilone √ (Mod) CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
quinidine ↑ THC Nabilone √ (Weak) CYP2E1 Substrate w/NTI √ DrugBank.ca 1/2/2020
quinidine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
rabeprazole ↑ CBD Cannabidiolol √ CYP2C19 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
ramelteon ↑↓ CBD Cannabidiolol √ √ CYP1A2 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
ramelteon ↓ THC/CBD Nabiximols √ CYP1A2 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
ramosetron ↑↓ CBD Cannabidiolol √ √ CYP1A2 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
ramosetron ↓ THC/CBD Nabiximols √ CYP1A2 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
repaglinide ↑ CBD Cannabidiolol √ CYP2C8 Sensitive Index Substrate (Table 2-1) √ FDA.gov 9/26/2016
repaglinide ↑ CBD Cannabidiolol √ CYP2C8 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
repaglinide ↑ THC Nabilone √ (Mod) CYP2C8 Sensitive Index Substrate (Table 2-1) √ FDA.gov 9/26/2016

List Updated April 13, 2020

While every attempt has been made to provide the most comprehensive list of potential drug-drug interactions,
there may be OTC, herbal, and prescription medications not included within this list. Page 5 of 7
 Cannabinoid (PRECIPITANT) Medication Affecting the Metabolism of Another (OBJECT) Medication
Pennsylvania State University, College of Medicine, Dept of Pharmacology (Hershey, PA)
https://sites.psu.edu/cannabinoid
Cannabinoid
Generic Name Medication Drug Effect Cannabinoid as the Enzyme Enzyme Source
Class Enzyme/Metabolism CYP1A2 CYP2B6 CYP2C8 CYP2C9 CYP2C19 CYP2E1 CYP3A4 UGT1A9 UGT2B7 Source
(OBJECT) (OBJECT) (PRECIPITANT) Inhibitor Inducer Date
(PRECIPITANT)
repaglinide ↑ THC Nabilone √ (Mod) CYP2C8 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
rilpivirine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
rilpivirine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
rilpivirine ↑↓ THC/CBD Nabiximols √ √ CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
rilpivirine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
rivaroxaban ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
rivaroxaban ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
rivaroxaban ↑↓ THC/CBD Nabiximols √ √ CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
rivaroxaban ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
rosiglitazone ↑ CBD Cannabidiolol √ CYP2C8 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
rosiglitazone ↑ THC Nabilone √ (Mod) CYP2C8 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
saquinavir ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
saquinavir ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
saquinavir ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
saquinavir ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
sildenafil ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
sildenafil ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
sildenafil ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
sildenafil ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
simvastatin ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
simvastatin ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
simvastatin ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
simvastatin ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
siponimod ↑ CBD Cannabidiolol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
siponimod ↑ THC Dronabinol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
siponimod ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
siponimod ↑ THC Nabilone √ (Mod) CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
siponimod ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
sirolimus ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
sirolimus ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
sirolimus ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
sirolimus ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
tacrolimus ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
tacrolimus ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
tacrolimus ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
tacrolimus ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
tadalafil ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
tadalafil ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
tadalafil ↑↓ THC/CBD Nabiximols √ √ CYP3A Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
tadalafil ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
tasimelteon ↑↓ CBD Cannabidiolol √ √ CYP1A2 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
tasimelteon ↓ THC/CBD Nabiximols √ CYP1A2 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
temsirolimus ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
temsirolimus ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
terfenadine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
terfenadine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
theophylline ↑↓ CBD Cannabidiolol √ √ CYP1A2 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
theophylline ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
theophylline ↓ THC/CBD Nabiximols √ CYP1A2 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
theophylline ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
theophylline ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
thiopental ↑ CBD Cannabidiolol √ CYP2C19 Substrate w/NTI √ DrugBank.ca 12/4/2019
tianeptine ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
tianeptine ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
ticagrelor ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
ticagrelor ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
ticagrelor ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
ticagrelor ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
tipranavir ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
tipranavir ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
tipranavir ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
tipranavir ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
tizanidine ↑↓ CBD Cannabidiolol √ √ CYP1A2 Sensitive Index Substrate (Table 2-1) √ FDA.gov 9/26/2016
tizanidine ↑↓ CBD Cannabidiolol √ √ CYP1A2 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
tizanidine ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
tizanidine ↓ THC/CBD Nabiximols √ CYP1A2 Sensitive Index Substrate (Table 2-1) √ FDA.gov 9/26/2016
tizanidine ↓ THC/CBD Nabiximols √ CYP1A2 Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
tizanidine ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
tolbutamide ↑ CBD Cannabidiolol √ CYP2C9 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
tolbutamide ↑ THC Dronabinol √ CYP2C9 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
tolbutamide ↑ THC Nabilone √ (Mod) CYP2C9 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019

List Updated April 13, 2020

While every attempt has been made to provide the most comprehensive list of potential drug-drug interactions,
there may be OTC, herbal, and prescription medications not included within this list. Page 6 of 7
 Cannabinoid (PRECIPITANT) Medication Affecting the Metabolism of Another (OBJECT) Medication
Pennsylvania State University, College of Medicine, Dept of Pharmacology (Hershey, PA)
https://sites.psu.edu/cannabinoid
Cannabinoid
Generic Name Medication Drug Effect Cannabinoid as the Enzyme Enzyme Source
Class Enzyme/Metabolism CYP1A2 CYP2B6 CYP2C8 CYP2C9 CYP2C19 CYP2E1 CYP3A4 UGT1A9 UGT2B7 Source
(OBJECT) (OBJECT) (PRECIPITANT) Inhibitor Inducer Date
(PRECIPITANT)
tolbutamide ↑ THC Dronabinol √ CYP2C9 Sensitive Index Substrate (Table 2-1) √ FDA.gov 9/26/2016
tolvaptan ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
tolvaptan ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
tolvaptan ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
tolvaptan ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
triazolam ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Index Substrate (Table 2-1) √ FDA.gov 9/26/2016
triazolam ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
triazolam ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
triazolam ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Index Substrate (Table 2-1) √ FDA.gov 9/26/2016
triazolam ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
triazolam ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
trimipramine ↑↓ CBD Cannabidiolol √ √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
trimipramine ↓ THC/CBD Nabiximols √ CYP2B6 Substrate w/NTI √ DrugBank.ca 1/2/2020
valproate (Hepatic Enzyme Elevation) ~ CBD Cannabidiolol ~ ~ Cannabidiol (Epidiolex®) Prescribing Information, 7.3 Prescribing Info 6/2018
valproic acid ↑ CBD Cannabidiolol √ UGT1A9 Substrate w/NTI √ DrugBank.ca 1/2/2020
valproic acid ↑ CBD Cannabidiolol √ UGT2B7 Substrate w/NTI √ DrugBank.ca 1/2/2020
valproic acid ↑ THC/CBD Nabiximols √ UGT1A9 Substrate w/NTI √ DrugBank.ca 1/2/2020
valproic acid ↑ THC/CBD Nabiximols √ UGT2B7 Substrate w/NTI √ DrugBank.ca 1/2/2020
valproic acid ↑ CBD Cannabidiolol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
valproic acid ↑ THC Dronabinol √ CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
valproic acid ↑ THC Nabilone √ (Mod) CYP2C9 Substrate w/NTI √ DrugBank.ca 12/4/2019
vardenafil ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
vardenafil ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
vardenafil ↑↓ THC/CBD Nabiximols √ √ CYP3A Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
vardenafil ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
voriconazole ↑ CBD Cannabidiolol √ CYP2C19 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
warfarin (VKA) ↑↓ CBD Cannabidiolol √ √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
warfarin (VKA) ↑ CBD Cannabidiolol √ CYP2C19 Substrate w/NTI √ DrugBank.ca 12/4/2019
warfarin (VKA) ↑ CBD Cannabidiolol √ CYP2C9 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
warfarin (VKA) ↑ THC Dronabinol √ CYP2C9 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
warfarin (VKA) ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
warfarin (VKA) ↑ THC Nabilone √ (Mod) CYP2C9 Moderate Sensitive Substrate (Table 3-1) √ FDA.gov 12/3/2019
warfarin (VKA) ↓ THC/CBD Nabiximols √ CYP1A2 Substrate w/NTI √ DrugBank.ca 1/2/2020
warfarin (VKA) ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
warfarin (VKA) S-Enantiomer ↑ THC Dronabinol √ CYP2C9 Sensitive Index Substrate (Table 2-1) √ FDA.gov 9/26/2016
zolpidem ↑ THC Dronabinol or Nabilone √ (Weak) CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019
zolpidem ↑↓ THC/CBD Nabiximols √ √ CYP3A4 Substrate w/NTI √ DrugBank.ca 12/5/2019

Legend:
The list of Cannabinoid (PRECIPITANT) medications are located in the 4th column from the left
OBJECT - The Medication Whose Metabolism is Potentially Disrupted by the Cannabinoid (PRECIPITANT) Medication
(VKA) Vitamin K Antagonist
(↑) Increase in Drug Effect of the OBJECT Medication
(↓) Decrease in Drug Effect of the OBJECT Medication
(↑↓) Increase and/or Decrease in Drug Effect of the OBJECT Medication
(THC) ∆9-tetrahydrocannabinol
(CBD) Cannabidiol
PRECIPITANT - The Cannabinoid Medication Potentially Disrupting the Metabolism of the OBJECT Medication
(PB) Protein Binding ≥85%

List Updated April 13, 2020

While every attempt has been made to provide the most comprehensive list of potential drug-drug interactions,
there may be OTC, herbal, and prescription medications not included within this list. Page 7 of 7